Arşiv logosu
  • Türkçe
  • English
  • Giriş
    Yeni kullanıcı mısınız? Kayıt için tıklayın. Şifrenizi mi unuttunuz?
Arşiv logosu
  • Koleksiyonlar
  • Sistem İçeriği
  • Analiz
  • Talep/Soru
  • Türkçe
  • English
  • Giriş
    Yeni kullanıcı mısınız? Kayıt için tıklayın. Şifrenizi mi unuttunuz?
  1. Ana Sayfa
  2. Yazara Göre Listele

Yazar "Beygi, Mohammad" seçeneğine göre listele

Listeleniyor 1 - 1 / 1
Sayfa Başına Sonuç
Sıralama seçenekleri
  • [ X ]
    Öğe
    Nano-phytoconstituents: Recent advances, regulatory insights, challenges, and future horizons
    (Elsevier, 2025) Beygi, Mohammad; Oroojalian, Fatemeh; Karav, Sercan; Kesharwani, Prashant; Sahebkar, Amirhossein
    Phytoconstituents possess therapeutic potency in human diseases, including antioxidant, antitumor, antiinflammatory, and anti-microbial impacts, as well as cardioprotective and neuroprotective capabilities. Nonetheless, they suffer from shortcomings like low solubility and bioavailability, fast degradation upon administration, and elevated doses required to exert therapeutic effects, culminating in potential adverse effects. As a solution to these, nanoscale drug delivery systems (DDSs) such as polymeric nanoparticles (NPs), lipid-based NPs, protein-based NPs, etc. are currently devised to realize intended goals in herbal medicine, which critically are sustained release and targeted delivery of phytomedicines to affected sites. Current DDSs are formulated to encapsulate diverse phytochemicals, including curcumin, berberine, resveratrol, quercetin, baicalin, and rosmarinic acid. The ultimate nanoassembly affords superior properties such as protracted circulation time, sustained release, site-specific delivery, synergistic effects (with antitumor agents), and measurable diseasealleviating effects. This article covers recent progress in nanophytomedicines and explores how DDSs can enrich the therapeutic properties of these phytochemicals. Further, the present article covers the regulatory aspects and ethical issues to be reflected when devising such DDSs, as well as the current standing of nanophytoconstituents in clinical trials.

| Çanakkale Onsekiz Mart Üniversitesi | Kütüphane | Açık Erişim Politikası | Rehber | OAI-PMH |

Bu site Creative Commons Alıntı-Gayri Ticari-Türetilemez 4.0 Uluslararası Lisansı ile korunmaktadır.


Çanakkale Onsekiz Mart Üniversitesi, Çanakkale, TÜRKİYE
İçerikte herhangi bir hata görürseniz lütfen bize bildirin

DSpace 7.6.1, Powered by İdeal DSpace

DSpace yazılımı telif hakkı © 2002-2025 LYRASIS

  • Çerez Ayarları
  • Gizlilik Politikası
  • Son Kullanıcı Sözleşmesi
  • Geri Bildirim